
Louis Navellier
Editor, Growth InvestorAn icon among growth stock investors
About Louis Navellier
Louis Navellier is one of Wall Street’s renowned growth investors. Providing investment advice to tens of thousands of investors for more than three decades, he has earned a reputation as a savvy stock picker and unrivaled portfolio manager.
Over his 35-year investing career, Louis Navellier has established one of the most exceptional long-term track records of any financial newsletter editor in America, and he offers a wide range of simple yet powerful tools that can help all investors to significantly beat the market.
His popular Growth Investor advisory service, established in 1998, has beaten the S&P 500 by a margin of 3-to-1 over the past 17 years.
Navellier continues to build on those stellar records, and while his methodology is rigorous and complex, his goal has been simple, and has been so from the beginning: to uncover Wall Street’s inconsistencies and help investors beat the market with less risk in the market’s best growth stocks. Today, he helps individual investors across the nation and across the globe achieve their financial dreams through his unique newsletter services.
The New York Times called Mr. Navellier “an icon among growth stock investors,” and the media frequently turns to Louis for his expert opinion. He appears regularly on CNBC and Fox Business News and is frequently quoted by MarketWatch, Bloomberg and The Wall Street Journal.
Navellier is an accomplished Wall Street insider as well. He and his team of more than 50 professional analysts and staff manage over $5 billion in mutual funds and institutional accounts through his fund management company, Navellier & Associates.
Louis Navellier also travels the country hosting free seminars for individual investors, and is the author of The Little Book That Makes You Rich, named one of the Top 10 Investing Books of 2007 by SFO Magazine.

Join Louis Navellier’s Market 360 — FREE!
Get Louis Navellier’s take on the news and events impacting the market, plus his top stock picks.
Premium Services
Louis Navellier’s Growth Investor provides an expert’s take on the latest market trends and opportunities. Then Louis shares his picks of High-Growth Investments and Elite Dividend Payers — complete with volatility ratings and buy-below prices.
-
Stocks (Mid- to Large-Cap)
-
Conservative
-
Monthly trades
Already a member? Login here
If you want growth, you’ve got to look at smaller up-and-comers that aren’t as well-known... yet. Louis Navellier’s Breakthrough Stocks lets you participate in high-quality small-caps — according to your personal risk tolerance.
-
Stocks (Small to Mid-Cap)
-
Moderate to Aggressive
-
Monthly trades
Already a member? Login here
Accelerated Profits uses Louis Navellier’s proprietary stock-rating system to identify High Velocity and Ultimate Growth Trades. By combining the “one-two punch” of strong momentum and fundamentals with a more frequent trading schedule, you get significant returns... in a fraction of the time.
-
Stocks (Large-Cap)
-
Aggressive
-
Weekly trades
Already a member? Login here
Louis Navellier’s Platinum Growth combines the top-notch investing strategies of Growth Investor and Breakthrough Stocks with the faster pace of Accelerated Profits — all in a powerful new way that could improve your results 10-fold or better.
-
Stocks
-
Conservative to Aggressive
-
Weekly and monthly trades
Already a member? Login here
Recent Articles
10 Semiconductor Stocks Not Living Up to Expectations
Some semiconductor stocks are thriving, but some continue to face headwinds. These ten are not living up to expectations.
A Pair of Potential Earnings Casualties
Even though there are a lot of reasons to be optimistic about this earnings season, JPMorgan (JPM) and Hasbro (HAS) are heading for trouble.
3 Winners to Expect This Earnings Season
Earnings season has begun -- and these three highly-rated stocks are expected to hit it out of the park.
10 Big Pharma Stocks to Buy
Pharmaceutical stocks and drugmakers are theoretically recession-proof businesses. Still, not all pharma companies are created equal. Here are 10 clear winners
10 Revved-Up Oil Companies to Buy
There has been a lot of volatility in the crude oil and energy sectors recently, but it appears that the winners are now separating themselves from the losers.
Jobs Recovery Helping to Revive the Economy
The unemployment rate in September was unchanged at 9.1%, but the Labor Dept. says 137,000 jobs were created in the private sector -- and markets took notice.
3 Reasons to Stick With Small Caps This Earnings Season
The third-quarter earnings season is approaching. Stock up on small-cap stocks in the coming days to take advantage of positive reports.
Don’t Fear the Street, But Forgo Financials
Banks (and their stocks) can't be trusted right now, but that's no reason not to invest. Look for smart buys big and small, and avoid financials as a whole.
9 Healthy Biotech Buys
Baby boomers are getting older and in need of more and more treatments, thus the race for the next big blockbuster drug. Smaller biotechs are cashing in.
5 Refreshing Consumer Stocks to Buy
Consumers are very reluctant to cut out the simple pleasures they know and love. Five beverage stocks in particular are quenching investors' thirst.